SEC Form 4 · accession 0001140361-18-000228
CYTRX CORP · CYTR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Felix Kratz
Officer — Vice President Drug Discovery
Period of report
Dec 15, 2017
Accepted (ET)
Jan 2, 2018 · 5:27 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000799698
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $1.75 | Dec 15, 2017 | A | 25,000 | A | — | Dec 14, 2027 | CytRx Common Stock | 25,000 | 25,000 | D |
Explanation of responses
- F1This grant constitutes the annual award of stock options to current employees.The stock option vests in equal installments every other month for 24 months, beginning February 15, 2018, provided Reporting Person remains in continuous employ of Issuer, or the conditions for immediate vesting occur.